Clinical Trial Update: Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL) [Phase 2]

View source ↗

Summary

A Phase II study of denileukin diftitox (Ontak) in previously treated patients with low-grade non-Hodgkin's lymphoma has completed, with results posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• ONTAK (denileukin diftitox)

Snippet

Sponsor: Eisai Inc. | Conditions: Non-Hodgkin's Lymphoma, Lymphoma, B-cell | Phase 2 | Status: COMPLETED | Results posted: 2011-08-03